Results 211 to 220 of about 5,994,707 (387)
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
The dopaminergic system of <i>Caenorhabditis elegans</i>. [PDF]
R Soc Open SciMuralidhara I, Hardege I.
europepmc +1 more source
A Receptor Mechanism for the Inhibition Of Insulin Release by Epinephrine in Man* [PDF]
, 1967 Daniel Porte
openalex +1 more source
Molecular Oncology, EarlyView.RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
Neurotransmitters in tumors: chemical cross-talk shaping tumor progression. [PDF]
Biomark ResChen W +8 more
europepmc +1 more source
Molecular Oncology, EarlyView.AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
The Endocannabinoid System in the Development and Treatment of Obesity: Searching for New Ideas. [PDF]
Int J Mol SciSerefko A +4 more
europepmc +1 more source